Large Loop Excision of the Transformation Zone (LLETZ) with Vs Without IntraOperative Application of Lugol's Iodine

NCT ID: NCT05132114

Last Updated: 2025-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

216 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-17

Study Completion Date

2025-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cervical cancer is one of the most common cancers in women and one of the leading causes of death in women worldwide. Pre-cancerous lesions (dysplasias) are detected by the gynecologist's preventive smear test and can thus contribute to a 100% chance of cure if they are clarified by a colposcopic examination as part of the dysplasia consultation and, if necessary, surgically removed. Conization (= surgical removal of a cone of tissue from the cervix) is the method of choice for removing the diseased tissue. LLETZ conization (Large Loop Excision of the Transformation Zone) is the worldwide standard surgical procedure for conization. There is risk of local persistence of the precancerous lesion if the cervical dysplasia is not completely removed. To minimize this, the iodine test can be used. Here, a 5% iodine solution (so-called Lugol's solution) is dabbed onto the cervix uteri, resulting in an intense and characteristic brown staining of the healthy cervical epithelium. Sites without staining are termed iodine negative and may contain dysplastic cells. The strength of iodine testing lies in its high specificity, i.e., the reliable ability to exclude false-positive results. The purpose of intraoperative iodine staining is to select the resection line with a high degree of certainty in healthy (i.e., iodine-positive) tissue in order to reduce the rate of cervical dysplasia that is not completely removed (so-called non-in-sano resection, or R1 resection). Systematic survey data from the dysplasia units certified in Germany on the question of the use of intraoperative iodine testing in Germany are lacking, as is the literature as a whole. For example, the current S3 guideline of the German Society of Gynecology and Obstetrics on the diagnosis and treatment of cervical dysplasia (as of March 2020) names intraoperative iodine testing only as a possible option for performing LLETZ.

In this prospective, randomized study, the investigators aim to answer the question whether LLETZ performed with the help of an iodine test with selection of the resection line in the iodine-positive area leads to a lower rate of R1 resections compared to the standard LLETZ without iodine test.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Background 1.1. HPV and dysplasias of the cervix uteri Human papillomaviruses (HPV) are the most common sexually transmitted pathogens worldwide. The prevalence in both male and female populations is high. Epidemiological estimates suggest that 85-91% of sexually active adults acquire at least one genital HPV infection by the age of 50, with approximately 95% of HPV infections being spontaneously eliminated within 2 years in terms of HPV immunological clearance. HPV preferentially infects the epithelial cells of the anogenital area and, through incorporation of HPV DNA into the host genome of the basal cells of the squamous epithelium of the cervix and subsequent expression of viral components, causes dysplastic changes in the cervical epithelium that, if left untreated, can develop into invasive carcinoma of the cervix (cervical carcinoma). Cervical carcinoma is the fourth most common cancer as well as the fourth leading cause of cancer-related death in women worldwide, responsible for 6.6% (570,000) of all new cancer cases and 7.5% (311,000) of cancer-related deaths in women in 2018. The precursor of squamous cell carcinoma of the uterine cervix (approximately 80% of all cervical cancers) is cervical intraepithelial neoplasia (CIN), which has three grades of expression (CIN1, CIN 2, and CIN 3). Compared with invasive cervical carcinoma, the incidence of precancerous lesions of the cervix uteri is much higher. It is estimated that approximately 100,000 women in Germany develop high-grade dysplasia (CIN2/CIN3) annually.

1.2. Surgical treatment If precancerous lesions with the potential to develop into an invasive cervical tumor are detected, conization (= surgical removal of a cone of tissue from the cervix) is the method of choice for removing the diseased tissue. Worldwide standard as surgical procedure for conization is LLETZ-conization (Large Loop Excision of the Transformation Zone). In addition to the risk of local persistence of the precancerous lesion if the cervical dysplasia is incompletely removed, LLETZ also increases the risk of preterm birth in a subsequent pregnancy. This risk increases with increasing volume of removed tissue. To reduce or avoid the aforementioned complications, conization should be performed under colposcopic vision and as little healthy cervical tissue as possible should be removed. One method of LLETZ that is as tissue-conserving as possible is the intraoperative use of the so-called 'iodine test'.

1.3. The iodine test For the identification of healthy squamous epithelium of the cervix uteri, the so-called Schiller's iodine test can be used, which has been part of the clinical routine in the context of colposcopy of cervical dysplasias for decades. In the iodine test, a 5% iodine solution (so-called Lugol's solution) is dabbed onto the cervix uteri, resulting in an intense and characteristic brown staining of the healthy cervical epithelium. Sites without staining are termed iodine negative and may contain dysplastic cells. The strength of iodine testing lies in its high specificity, i.e., the reliable ability to exclude false-positive results. Not all iodine-negative areas contain CIN, but iodine-positive areas are almost certainly healthy. In some centers, because of these characteristics of the iodine sample, it is used during LLETZ to define the resection line of LLETZ. The aim of this approach is to select the resection line with a high degree of certainty in healthy (i.e., iodine-positive) tissue in order to reduce the rate of cervical dysplasia that is not completely removed (so-called 'non-in-sano resection' or 'R1 resection'). Systematic survey data from the dysplasia units certified in Germany on the question of the use of intraoperative iodine testing in Germany are lacking. The current S3 guideline of the German Society of Gynecology and Obstetrics on the diagnosis and therapy of cervical dysplasia (as of March 2020) also refers to intraoperative iodine testing as a possible option for performing LLETZ. However, exact figures from controlled studies on the usefulness of iodine test-guided LLETZ are lacking in the literature (PubMed search on 10/15/2021; search terms: cervical dysplasia, colposcopy, Lugol's test, iodine test, Lugol's staining; LLETZ; LEEP; conization). At our certified dysplasia center, it is the decision of the respective surgeon whether an additional intraoperative iodine test is performed or not.
2. Aim of the study The aim of this study is to answer the question under prospective randomized conditions whether LLETZ performed with the aid of iodine assay with selection of the resection line in the iodine-positive region leads to a lower rate of R1 resections compared with standard LLETZ without iodine assay.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Dysplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Prospective randomized trial with 2 groups (use vs not use of Lugol's iodine during LLETZ)
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants
Participants are not aware of their treatment allocation in order not to influence patient reported outcomes

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control Group

LLETZ (without intraoperative Lugol's iodine)

Group Type NO_INTERVENTION

No interventions assigned to this group

Iodine group

LLETZ after the intraoperative application of Lugol's iodine

Group Type EXPERIMENTAL

Lugol's iodine test

Intervention Type DIAGNOSTIC_TEST

Intraoperative application of Lugol's iodine (i.e. staining of the cervix with Lugol's iodine solution)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lugol's iodine test

Intraoperative application of Lugol's iodine (i.e. staining of the cervix with Lugol's iodine solution)

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written consent
* Colposcopy performed preoperatively
* Histologically (by previously performed colposcopy) confirmed dysplasia (CIN 1, CIN 2 or CIN 3)
* Age \>18 years

Exclusion Criteria

* Pregnant patients
* Patients with insufficient knowledge of the German language
* Treatments already performed on the cervix uteri, in particular conization
* Blood coagulation disorders
* Taking blood thinning substances
* Iodine allergy
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ruhr University of Bochum

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Clemens Tempfer

Director, Department of Obstetrics and Gynecologiy

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clemens B Tempfer, MD, MBA

Role: PRINCIPAL_INVESTIGATOR

Ruhr-Universität Bochum / Marien Hospital Herne

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Marien Hospital Herne

Herne, North Rhine-Westphalia, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Clemens B Temfper, MD, MBA

Role: CONTACT

+492323499 ext. 1801

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Clemens B Tempfer, MD, MBA

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021 Jul 23;70(4):1-187. doi: 10.15585/mmwr.rr7004a1.

Reference Type BACKGROUND
PMID: 34292926 (View on PubMed)

Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014 Nov;41(11):660-4. doi: 10.1097/OLQ.0000000000000193.

Reference Type BACKGROUND
PMID: 25299412 (View on PubMed)

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.

Reference Type BACKGROUND
PMID: 30207593 (View on PubMed)

Mathevet P, Chemali E, Roy M, Dargent D. Long-term outcome of a randomized study comparing three techniques of conization: cold knife, laser, and LEEP. Eur J Obstet Gynecol Reprod Biol. 2003 Feb 10;106(2):214-8. doi: 10.1016/s0301-2115(02)00245-2.

Reference Type BACKGROUND
PMID: 12551795 (View on PubMed)

Bevis KS, Biggio JR. Cervical conization and the risk of preterm delivery. Am J Obstet Gynecol. 2011 Jul;205(1):19-27. doi: 10.1016/j.ajog.2011.01.003. Epub 2011 Feb 23.

Reference Type BACKGROUND
PMID: 21345402 (View on PubMed)

Jin G, LanLan Z, Li C, Dan Z. Pregnancy outcome following loop electrosurgical excision procedure (LEEP) a systematic review and meta-analysis. Arch Gynecol Obstet. 2014 Jan;289(1):85-99. doi: 10.1007/s00404-013-2955-0. Epub 2013 Jul 11.

Reference Type BACKGROUND
PMID: 23843155 (View on PubMed)

Khalid S, Dimitriou E, Conroy R, Paraskevaidis E, Kyrgiou M, Harrity C, Arbyn M, Prendiville W. The thickness and volume of LLETZ specimens can predict the relative risk of pregnancy-related morbidity. BJOG. 2012 May;119(6):685-91. doi: 10.1111/j.1471-0528.2011.03252.x. Epub 2012 Feb 14.

Reference Type BACKGROUND
PMID: 22329499 (View on PubMed)

Shaco-Levy R, Eger G, Dreiher J, Benharroch D, Meirovitz M. Positive margin status in uterine cervix cone specimens is associated with persistent/recurrent high-grade dysplasia. Int J Gynecol Pathol. 2014 Jan;33(1):83-8. doi: 10.1097/PGP.0b013e3182763158.

Reference Type BACKGROUND
PMID: 24300540 (View on PubMed)

Preaubert L, Gondry J, Mancini J, Chevreau J, Lamblin G, Atallah A, Lavoue V, Caradec C, Baldauf JJ, Bryand A, Henno S, Villeret J, Agostini A, Douvier S, Jarniat A, Riethmuller D, Mendel A, Brun JL, Rakotomahenina H, Carcopino X. Benefits of Direct Colposcopic Vision for Optimal LLETZ Procedure: A Prospective Multicenter Study. J Low Genit Tract Dis. 2016 Jan;20(1):15-21. doi: 10.1097/LGT.0000000000000156.

Reference Type BACKGROUND
PMID: 26704328 (View on PubMed)

Kuhn W. [Colposcopy in the diagnosis of early cervical cancer]. Pathologe. 2011 Nov;32(6):497-504. doi: 10.1007/s00292-011-1480-9. German.

Reference Type BACKGROUND
PMID: 21984389 (View on PubMed)

Hilal Z, Rezniczek GA, Alici F, Kumpernatz A, Dogan A, Alieva L, Tempfer CB. Loop electrosurgical excision procedure with or without intraoperative colposcopy: a randomized trial. Am J Obstet Gynecol. 2018 Oct;219(4):377.e1-377.e7. doi: 10.1016/j.ajog.2018.07.023. Epub 2018 Jul 29.

Reference Type BACKGROUND
PMID: 30063903 (View on PubMed)

Rezniczek GA, Hecken JM, Rehman S, Dogan A, Tempfer CB, Hilal Z. Syringe or mask? Loop electrosurgical excision procedure under local or general anesthesia: a randomized trial. Am J Obstet Gynecol. 2020 Dec;223(6):888.e1-888.e9. doi: 10.1016/j.ajog.2020.06.041. Epub 2020 Jul 24.

Reference Type BACKGROUND
PMID: 32585223 (View on PubMed)

Hilal Z, Rezniczek GA, El-Fizazi N, Tempfer CB. Large Loop Excision of the Transformation Zone Versus True Cone Biopsy Electrode Excision: A Randomized Trial. J Low Genit Tract Dis. 2017 Oct;21(4):272-278. doi: 10.1097/LGT.0000000000000329.

Reference Type BACKGROUND
PMID: 28953118 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LLETZ-IOLI-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.